Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Annovis Bio Inc
(NY:
ANVS
)
8.530
-0.320 (-3.62%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Annovis Bio Inc
< Previous
1
2
3
4
5
Next >
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2022
September 08, 2022
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
Via
Benzinga
FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap
July 07, 2022
Via
Benzinga
Annovis Shares Gain As Late-Stage Parkinson's Disease Study Takes-off
August 24, 2022
Annovis Bio, Inc. (NYSE: ANVS) has initiated patient dosing in the Phase 3 clinical trial evaluating buntanetap in early Parkinson's Disease (PD). The Phase 3 trial is designed to evaluate the...
Via
Benzinga
Publication Of Peer-Reviewed Study In Journal Of The Alzheimer's Association Could Mark A Significant Step For Longeveron
August 02, 2022
Recent publishing of Longeveron Inc.’s (NASDAQ: LGVN)
Via
Benzinga
Dear AMC Stock Fans, Mark Your Calendars for Aug. 4
July 07, 2022
AMC Entertainment (AMC) stock is in the news today as investors in the theater company prepare for a potential catalyst coming next month!
Via
InvestorPlace
Annovis Bio (ANVS) Stock Soars 6% on Positive FDA Update
July 07, 2022
Annovis Bio (ANVS) stock is soaring higher on Thursday following a positive update from the FDA for its buntanetap clinical trial.
Via
InvestorPlace
Annovis Bio Gets FDA Nod For Late-Stage Parkinson Disease Study Amendments
July 07, 2022
The United States Food and Drug Administration (FDA) announced clearance for amendments to Annovis Bio’s (NYSE: ANVS) Phase 3 clinical study of Buntanetap for the treatment of Parkinson's disease.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
July 07, 2022
Via
Benzinga
83 Biggest Movers From Yesterday
June 09, 2022
Gainers Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly...
Via
Benzinga
50 Stocks Moving In Wednesday's Mid-Day Session
June 08, 2022
Gainers HeartCore Enterprises, Inc. (NASDAQ: HTCR) shares gained 81% to $1.8503 after the company authorized a $3.5 million buyback.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2022
May 02, 2022
Upgrades
Via
Benzinga
The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid
April 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease
January 25, 2022
Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 27, 2021
Gainers OptiNose (NASDAQ:OPTN) shares mov...
Via
Benzinga
Annovis Bio on Its Positive Results in Alzheimer's and Parkinson's Clinical Trials
December 27, 2021
Image provided by Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
December 03, 2021
Gainers Lixte Biotech Holdings (NASDAQ:LIXT
Via
Benzinga
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
November 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...
Via
Benzinga
Why Cortexyme Thinks It Could Be Next In The Mega Alzheimer's Drug Market
October 21, 2021
Cortexyme is testing a twice-day pill to treat Alzheimer's disease.
Via
Investor's Business Daily
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
November 09, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces...
Via
Benzinga
44 Biggest Movers From Yesterday
October 15, 2021
Gainers Benessere Capital Acquisition Corp. (NASDAQ: BENER) shares jumped 66.5% to close at $0.4530 on Thursday. Grove, Inc. (NASDAQ: GRVI) gained 39.3% to close at $6.98 after...
Via
Benzinga
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
3 Stocks Insiders Are Buying
October 14, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go...
Via
Benzinga
92 Biggest Movers From Friday
November 08, 2021
Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...
Via
Benzinga
EXCLUSIVE: Annovis Bio's Parkinson's Candidate Improves Speed, Motor Function Vs Placebo
October 05, 2021
Annovis Bio Inc (NYSE: ANVS) has announced efficacy data from the Phase 2 trial evaluating ANVS401 in Parkinson's disease (PD). Data from 54 patients found that once-...
Via
Benzinga
The Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
August 26, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 25) Abbvie Inc. (NYSE: ABBV)...
Via
Benzinga
Exposures
COVID-19
Better Biotech Stock: Cassava Sciences vs. Annovis Bio
August 26, 2021
It boils down to which company's clinical trial results look better for treating Alzheimer's at the moment.
Via
The Motley Fool
Why Is Biogen Pursuing a New Direction in Alzheimer's Research?
August 13, 2021
It might be that Biogen, too, is abandoning the theory that amyloid plaque is the cause of the disease.
Via
The Motley Fool
61 Biggest Movers From Yesterday
August 03, 2021
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares climbed 124.8% to close at $5.08 on Monday after the company announced a $5 million stock repurchase program....
Via
Benzinga
99 Biggest Movers From Yesterday
August 06, 2021
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.